Shield Therapeutics (LON:STX) Shares Down 23.5% – Time to Sell?

Shares of Shield Therapeutics plc (LON:STX) traded down 23.5% during trading on Thursday . The company traded as low as GBX 4.25 and last traded at GBX 4.40. Approximately 24,498,359 shares traded hands during mid-day trading, an increase of 1,091% from the average session volume of 2,056,888 shares. The stock had previously closed at GBX 5.75.

Shield Therapeutics Stock Performance

The company has a current ratio of 0.90, a quick ratio of 2.16 and a debt-to-equity ratio of -199.87. The company has a market cap of £47.06 million, a PE ratio of -2.20 and a beta of 1.76. The firm’s 50-day simple moving average is GBX 6.14 and its two-hundred day simple moving average is GBX 8.07.

Shield Therapeutics Company Profile

Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.